Clinical Trial Update: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

View source ↗

Summary

Takeda-sponsored clinical trial evaluating brigatinib as a preferred first-line therapy for adults with non-small cell lung cancer is currently active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: Takeda | Conditions: Non-small Cell Lung Cancer (NSCLC) | Status: ACTIVE_NOT_RECRUITING